Downstaging of a gastroenteropancreatic neuroendocrine tumor after combination therapy of temozolomide, Bevacizumab and long-acting somatostatin analogs Abstract #114

Introduction: Patients with gastroenteropancreatic endocrine (GEP) tumors and progressive disease have been treated with several chemotherapeutic regimens with variable responses and considerable toxicity. Recent studies have shown that GEP tumors may respond to therapy with anti-angiogenic agents, mainly as a result of their increased vascularity.
Aim(s): Description of the efficacy and change of therapeutic approach of concomitant administration of an alkylatic agent temozolomide, with the monoclonal antibody against VEGF, bevacizumab, along with the long-acting somatostatin analog in a patient with a inoperable GEP tumor.
Materials and methods: We describe a 75-year-old male patient who was found, using abdominal computerized tomography, to have an eight cm GEP tumor originating from either the stomach or the duodenum, encasing the whole duodenum and pancreas and compressing the liver. There was no other evidence of disease dissemination. Scintigraphy with 111In-octreotide demonstrated moderate uptake. An unsuccessful attempt was made initially to remove the tumor. Histology revealed a well-differentiated GEP tumor exhibiting 4 mitoses/OF and a Ki-67 proliferative index (PI) of 10%. The patient was treated with six cycles of combination treatment including: temozolomide 100mg/daily orally, intravenous bevacizumab 7.5mg/m2/3 weeks, and 30 mg of octreotide LAR/four weeks (ΤeBeSa). During treatment, he developed grade 1 nausea that was successfully managed with metoclopramide tablets.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Stavroula Antoniou

To read results and conclusion, please login ...

Further abstracts you may be interested in

#55 Metronomic combination therapy including temozolamide, bevacizumab and somatostatin analogue for the treatment of malignant gastroenteropancreatic neuroendocrine tumors
Introduction: Malignant gastroenteropancreatic neuroendocrine tumors (GEPNETS), mainly carcinoids, are not considered to be particularly chemotherapy-sensitive to conventional chemotherapeutic schemes. Long-standing evidence suggests these tumors to be highly vascularised and responsive to antiangiogenic strategies. Newest reports demonstrate benefit by the use of temozolamide, an oral alkylating agent similar to intravenous dacarbazine. The DNA repair enzyme O6-alkylguanine–DNA alkyltransferase (AGAT) confers cancer cell resistance to O6-alkylating agents such as temozolamide through its ability to remove methyl/alkyl groups from the O6-position of guanine, thus correcting drug-induced DNA damage.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: DR Anna Koumarianou
#2094 Disease Control in Progressive Pancreatic and Intestinal Neuroendocrine Tumors by Combined Treatment with Lanreotide Autogel and Temozolomide: The SONNET Study
Introduction: In advanced NETs antiproliferative treatment options beyond somatostatin analogues remain limited. Temozolomide (TMZ) has shown efficacy in NETs alone or combined with other drugs.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Prof Marianne Pavel
Authors: Pavel M, Denecke T, Lahner H, Hörsch D, ...
#2265 Activity of Bevacizumab in Neuroendocrine Neoplasms
Introduction: The combination of the anti-VEGF antibody bevacizumab (BEV) with a multitude of other antineoplastic substances has shown promising activity in neuroendocrine neoplasms (NEN). However, data proving the superiority of BEV-containing vs. BEV-free protocols are lacking.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment -Targeted therapies
Presenting Author: Dr. med. Leonidas Apostolidis
#313 Effect of Somatostatin Analogues in the Control of Tumor Growth in Patients with Metastatic Lung Carcinoid Tumors
Introduction: Antitumor effect of Somatostatin analogues has been poorly documented in metastatic typical or atypical lung carcinoid tumors (LCT).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Pr Joël Guigay
#82 A case of insulinoma successfully treated by means of long-acting somatostatin analogue
Introduction: Insulinoma is the most common hormonally active pancreatic neuroendocrine tumor. Effective treatment represents tumor surgery and medical therapy using diazoxide or streptozotocine. Somatostatin analogue therapy is rarely effective in this type of tumor.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof Marek Bolanowski